Nonetheless, no RCTs to date, other than a post hoc analysis of the DECLARE-TIMI 58 trial [15] address the relationship between SGLT2 inhibitors and the risk of AF/AFL in the population. This evidence concerns the gene SLC5A2 and atrial fibrillation.